SCHEMBL1883472

SCHEMBL1883472

C/C=C/c1ccccc1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 5/20 0.64
TRPA1 O75762 1/20 0.64
TFEB P19484 1/20 0.60
CYP1A1 P04798 3/20 0.58
CYP1A2 P05177 3/20 0.58
CYP1B1 Q16678 3/20 0.58
KDM4E B2RXH2 2/20 0.58
CYP19A1 P11511 1/20 0.56
CYP3A4 P08684 2/20 0.54
HMGCR P04035 1/20 0.54
NPC1 O15118 2/20 0.53
MAPT P10636 2/20 0.53
RAB9A P51151 2/20 0.53
LMNA P02545 1/20 0.53
BCHE P06276 1/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA4 P22748 1/20 0.52
CA7 P43166 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1883475 1.00 NFE2L2 (0.64) NFE2L2TRPA1TFEBCYP1A1CYP1A2
SCHEMBL4461398 1.00 NFE2L2 (0.64) NFE2L2TRPA1TFEBCYP1A1CYP1A2
SCHEMBL29580852 1.00 NFE2L2 (0.64) NFE2L2TRPA1TFEBCYP1A1CYP1A2
SCHEMBL7915752 0.88 NFE2L2 (0.79) NFE2L2TRPA1TFEBCYP1A1CYP1A2
SCHEMBL1603719 0.88 NFE2L2 (0.79) NFE2L2TRPA1TFEBCYP1A1CYP1A2
SCHEMBL4019329 0.88 NFE2L2 (0.79) NFE2L2TRPA1TFEBCYP1A1CYP1A2
SCHEMBL3669785 0.84 NFE2L2 (0.45) NFE2L2TRPA1TFEBCYP1A1CYP1A2
SCHEMBL21110871 0.84 NFE2L2 (0.45) NFE2L2TRPA1TFEBCYP1A1CYP1A2
SCHEMBL6158840 0.83 NFE2L2 (0.55) NFE2L2TRPA1TFEBCYP1A1CYP1A2
SCHEMBL16933894 0.82 NFE2L2 (0.64) NFE2L2TRPA1TFEBCYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1455937-B1 CHELATING CARBENE LIGAND PRECURSORS AND THEIR USE IN THE SYNTHESIS OF METATHESIS CATALYSTS MATERIA INC (US) 2018-04-11 EP claimed
US-7268242-B2 Contacting a metathesis-active metal carbene complex with an internal olefin ligand precursors followed by crystallization from an organic solvent MATERIA, INC. (US) 2007-09-11 US claimed
US-7026495-B1 Using beta-substituted styrenes instead of terminal olefin compounds such as unsubstituted styrenes to react with a ruthenium complex;recovered and reused; oxidation resistance; storage stability; efficiency; polymerization; cuprous chloride-free and nontoxic; materials handling MATERIA, INC. (US) 2006-04-11 US claimed
US-20230322647-A1 PCNHCP METAL COMPLEXES AND USES THEREOF TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2023-10-12 US disclosed
US-20230322647-A1 PCNHCP METAL COMPLEXES AND USES THEREOF TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2023-10-12 US disclosed
US-20230209856-A1 LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2023-06-29 US disclosed
US-20230025356-A1 COMPOSITION, LAYER INCLUDING THE COMPOSITION, LIGHT-EMITTING DEVICE INCLUDING THE COMPOSITION, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-01-26 US disclosed
US-20220402952-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2022-12-22 US disclosed
US-11396505-B2 Inhibitors of CaMKK2 and uses of same NEW YORK UNIVERSITY (US) 2022-07-26 US disclosed
WO-2022139513-A1 COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME 주식회사 엘지화학 2022-06-30 WO disclosed
US-20200369656-A1 INHIBITORS OF CAMKK2 AND USES OF SAME NEW YORK UNIVERSITY 2020-11-26 US disclosed
EP-1045842-A2 METHODS OF USE AND COMPOSITIONS FOR BENZYLIDENE- AND CINNAMYLIDENE-ANABASEINES University of Florida (US) 2000-10-25 EP disclosed
US-5977144-A Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines UNIVERSITY OF FLORIDA (US) 1999-11-02 US disclosed
WO-1999010338-A2 BENZYLIDENE- AND CINNAMYLIDENE-ANABASEINES AS NEURONAL NICOTINIC ALPHA-7 RECEPTOR AGONISTS UNIVERSITY OF FLORIDA (US) 1999-03-04 WO disclosed
EP-0350069-B1 METHOD FOR OXIDIZING UNSATURATED AROMATIC COMPOUNDS NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) 1993-03-17 EP disclosed
US-4994539-A Ethylene-unsaturated aromatic copolymer NIPPON PETROCHEMICALS CO., LTD. (JP) 1991-02-19 US disclosed
US-4967009-A REACTING UNSATURATED AROMATIC COMPOUNDS WITH AROMATIC IODOSYL COMPOUNDS TO YIELD AROMATIC ALDEHYDES OR KETONES NIPPON PETROCHEMICALS CO., LTD. (JP) 1990-10-30 US disclosed
EP-0350069-A2 Method for oxidizing unsaturated aromatic compounds NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) 1990-01-10 EP disclosed
EP-0104863-B1 LIGHT-SENSITIVE PLANOGRAPHIC PRINTING PLATE FUJI PHOTO FILM CO., LTD. (JP) 1989-05-03 EP disclosed
EP-0180771-A1 Method for improving impulse breakdown strength of electrically insulating materials Nippon Petrochemicals Co., Ltd. (JP) 1986-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025356-A1 COMPOSITION, LAYER INCLUDING THE COMPOSITION, LIGHT-EMITTING DEVICE INCLUDING THE COMPOSITION, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE LAGE3, ITK, TEC NFE2L2 1079/4885TRPA1 972/4885TFEB 829/4885
US-20220402952-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE ORC3, L1CAM, ICOSLG NFE2L2 113/4885TRPA1 322/4885TFEB 1658/4885
US-11396505-B2 Inhibitors of CaMKK2 and uses of same CAMKK2, CAMKK1, CAMK1 NFE2L2 822/4885TRPA1 4734/4885TFEB 2492/4885
US-20230322647-A1 PCNHCP METAL COMPLEXES AND USES THEREOF PIN4, HIRIP3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 NFE2L2 1726/4885TRPA1 2039/4885TFEB 861/4885
US-20200369656-A1 INHIBITORS OF CAMKK2 AND USES OF SAME CAMKK2, CAMKK1, CAMK1 NFE2L2 822/4885TRPA1 4734/4885TFEB 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.